Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus CLOXACILLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus CLOXACILLIN SODIUM.
BICILLIN L-A vs CLOXACILLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Cloxacillin is a beta-lactam antibiotic that binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidases and thus preventing the cross-linking of peptidoglycan chains. This leads to cell lysis and death, primarily mediated by autolytic enzymes. It is resistant to penicillinase (beta-lactamase) produced by staphylococci.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
250-500 mg orally every 6 hours on an empty stomach; 250 mg - 2 g IV/IM every 4-6 hours depending on severity; maximum 12 g/day for serious infections.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
0.5-1.1 hours in adults with normal renal function; prolonged in neonates, elderly, and renal impairment (up to 2-4 hours in anuria)
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Renal (70-80% unchanged via glomerular filtration and tubular secretion); biliary/fecal (small amount, <10%)
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic